# Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine

> **NCT07655180** · PHASE3 · RECRUITING · sponsor: **Invivyd, Inc.** · enrollment: 210 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** COVID-19 mRNA vaccine
- **DRUG:** VYD2311
- **DRUG:** Placebo (Normal Saline)

## Key facts

- **NCT ID:** NCT07655180
- **Lead sponsor:** Invivyd, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-08
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07655180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07655180, "Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07655180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*